CIBC Private Wealth Group’s NewAmsterdam Pharma NAMS Stock Holding History

CIBC Private Wealth Group’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$254K	Sell	7,240 -400	-5%	-$14.6K	﹤0.01%	1085
2025 Q3	$217K	Hold	7,640	–	–	﹤0.01%	1149
2025 Q2	$138K	Hold	7,640	–	–	﹤0.01%	1265
2025 Q1	$116K	Hold	7,640	–	–	﹤0.01%	1300
2024 Q4	$195K	Hold	7,640	–	–	﹤0.01%	1164
2024 Q3	$127K	Sell	7,640 -5,000	-40%	-$86.5K	﹤0.01%	1384
2024 Q2	$253K	Buy	12,640 +5,000	+65%	+$100K	﹤0.01%	1008
2024 Q1	$163K	Buy	+7,640	New	+$155K	﹤0.01%	1203
2023 Q4	–	Sell	-13,000	Closed	-$120K	–	1166
2023 Q3	$120K	Buy	+13,000	New	+$141K	﹤0.01%	1029

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CIBC Private Wealth Group's NAMS Position: Q4 2025 in Review

CIBC Private Wealth Group reduced its NewAmsterdam Pharma (NAMS) stake by 5.2% in Q4 2025, selling an estimated $14.6K and leaving 7,240 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #1085.

CIBC Private Wealth Group first reported a position in NAMS in Q3 2023 and has held it in 9 quarters since. 186 funds tracked by Wall St. Rank hold NAMS as of Q4 2025.

CIBC Private Wealth Group held 7,240 shares of NewAmsterdam Pharma worth $254K as of Q4 2025.
CIBC Private Wealth Group sold 400 NewAmsterdam Pharma shares in Q4 2025, an estimated $14.6K.
NewAmsterdam Pharma made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #1085 holding.
CIBC Private Wealth Group first reported a position in NewAmsterdam Pharma in Q3 2023 and has held it in 9 quarters since.
186 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.